Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06976203 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
A Phase 3 study of Alzheimers Disease, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 586
- Enrollment target
- 20
- Study locations
NCT06976203: Recruiting Phase 3 study of Alzheimers Disease, sponsored by Bristol-Myers Squibb.
NCT06976203 is a Phase 3 study of Alzheimers Disease that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 586 participants, below the 3,922-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06976203, a Phase 3 study of Alzheimers Disease, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 586 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Conditions Studied
Interventions
- OTHER Placebo
- DRUG KarXT
- DRUG KarX-EC
Study Locations (20)
Florida
- Neuropsychiatric Research Center of Southwest Florida - Fort Myers
- Velocity Clinical Research, Hallandale Beach - Hallandale
- Jacksonville Center for Clinical Research - Jacksonville
- K2 MEDICAL Research THE VILLAGES - Lady Lake
- Intercoastal Medical Group - Sarasota
- USF Health Byrd Alzheimer's Institute - Tampa
- Alzheimer's Research and Treatment Center - Wellington
California
- Fullerton Neurology and Headache Center - Fullerton
- Inglewood Clinical - Inglewood
- Irvine Clinical Research - Irvine
- Local Institution - 0083 - Palo Alto
- Local Institution - 0069 - San Diego
Illinois
- Great Lakes Clinical Trials - Andersonville - Chicago
- Southern Illinois University School of Medicine - Springfield
Colorado
- Research of the Rockies - Colorado Springs
Indiana
- Josephson Wallack Munshower Neurology, PC - Indianapolis
Massachusetts
- Local Institution - 0080 - Watertown
Michigan
- QUEST Research Institute - Farmington Hills
Mississippi
- Private Practice - Dr. Ronald Louis Schwartz - Hattiesburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 586 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2029-02-23 |
| Phase | Phase 3 |
What NCT06976203 shows while recruiting
NCT06976203 is an interventional study that assigns participants to a tested intervention. The registered 586 participants enrollment target is mid-sized for trials with a published cap, below the 3,922-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06976203 names 20 study sites across 9 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06976203 about?
NCT06976203 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)". The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
What is the current status of trial NCT06976203?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 586 participants. The study started on 2025-07-21. Estimated completion is 2029-02-23.
What conditions does trial NCT06976203 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT06976203?
The interventions under investigation include: Placebo (OTHER), KarXT (DRUG), KarX-EC (DRUG).
Who is sponsoring clinical trial NCT06976203?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06976203 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06976203's enrollment target sits among peer trials
586 26th of 147 higher than 121 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
- NCT06183281 · 586 participants · NA
Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity
- NCT07035093 · 586 participants · Phase 3
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI